Results of Biomarck Clinical and Preclinical Studies of BIO-11006 in ARDS to be Presented at the 2021 ARDS Drug Development Summit

Biomarck Pharmaceuticals

NEWTOWN, PA — Biomarck Pharmaceuticals, Ltd. announced that data from clinical and preclinical studies of BIO-11006, the Company’s lead peptide, will be presented during the 2021 ARDS Drug Development Summit, a virtual event being held July 13 – 15, 2021.

n the Phase 2 clinical study, rapid and faster improvements in oxygenation were observed in patients receiving BIO-11006 compared to placebo (half normal saline), together with decreases in pro-inflammatory cytokines. At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm.

BIO-11006 was effective in three preclinical mouse models, lipopolysaccharide (LPS), Strep. pneumoniae and lipoteichoic acid (LTA). Treatment with BIO-11006 prevented development of ARDS, reversed established ARDS and prevented neutrophil influx into the lungs.

Professor Kenneth Adler, PhD, Professor of Cell Biology at North Carolina State University’s College of Veterinary Medicine, and Presenter at the Summit, commented, “Compelling evidence of efficacy has been demonstrated with BIO-11006 in preclinical models and in a Phase 2 study. It is hoped that these results can now be repeated in a larger clinical trial currently being planned.”

READ:  Norman's Hallmark Recaps Top-Selling Holiday Gifts – So Far – for 2021

The presentation will be available after the summit on the Biomarck website in the Publications section

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.